STOCK TITAN

Evogene Stock Price, News & Analysis

EVGN Nasdaq

Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.

Evogene Ltd. (EVGN) is a computational biology and chemistry company that regularly publishes news about its AI‑driven platforms, collaborations and corporate developments. The EVGN news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Evogene applies big data and artificial intelligence to life‑science product discovery in pharmaceuticals and agriculture.

Recent announcements highlight Evogene’s focus on ChemPass AI, its generative AI tech‑engine for small‑molecule design and optimization. News items include the completion of a generative AI foundation model for small‑molecule design developed with Google Cloud, as well as updates on how ChemPass AI is being positioned as the core engine for the company’s pharma and agricultural activities.

Evogene’s news also covers scientific collaborations, such as agreements with Unravel Biosciences to design small‑molecule therapeutics for demyelinating diseases and with a Tel Aviv University research group to develop small molecules targeting metabolite self‑assembly in metabolic diseases. In agriculture, readers can find updates related to subsidiaries like Casterra Ag, including partnerships to advance mechanized castor farming for bio‑based industries.

In addition, the EVGN news stream features financial and corporate communications, including quarterly results, conference call schedules, investor conference presentations, restructuring steps and transactions such as the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. Investors and observers can use this page to monitor how Evogene’s strategy, partnerships and technology platforms evolve over time.

Rhea-AI Summary

Casterra Ag , a subsidiary of Evogene (NASDAQ: EVGN), announced a new purchase order valued at approximately $440K to supply castor seeds to a new African country. This expansion reflects confidence in Casterra's biofuel market capabilities and leverages Evogene's GeneRator AI tech. The company expects its 900-ton seed production to fulfill this order by Q4 2024. Unfulfilled orders from 2023 and new 2024 orders are anticipated to bring in around $8.4 million in revenue in the second half of 2024. The biodiesel market, estimated at $36.48 billion in 2022, is projected to grow significantly, favoring sustainable biofuel alternatives like Casterra's castor oil, which is compliant with stringent European standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Biomica , a subsidiary of Evogene, released promising preliminary data from a Phase 1 trial of BMC128, a microbiome-based immuno-oncology candidate, in combination with nivolumab. This trial involves patients with refractory NSCLC, melanoma, or RCC. Key findings include an exceptional safety profile with no major safety events, 72% of refractory cases showing positive clinical signals, and 64% of patients demonstrating stable disease. Additionally, 55% of patients showed sustained clinical benefits beyond 16 weeks, with some exceeding 80 weeks. The data will be presented at the 2024 ASCO annual meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
-
Rhea-AI Summary

Evogene (NASDAQ: EVGN) reported its Q1 2024 financial results, showing significant improvements. Revenues increased to $4.2M from $0.6M in Q1 2023, driven by Lavie Bio's licensing agreement with Corteva and AgPlenus's collaboration with Bayer. Net loss reduced to $3.8M from $7.0M in the previous year. Projected 2024 cash usage is expected to decrease by 36% to $8.0M. Ceasing Canonic operations will save $1.5M annually. Key developments include Biomica's Phase 1 trial data presentation, Lavie Bio's new collaborations, and AgPlenus's agreement with Bayer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
Rhea-AI Summary

Casterra Ag has signed new agreements with seed producers in Africa to meet the growing demand for its elite castor seeds. These agreements will support the production of approximately 500 tons of additional seeds, ensuring the fulfillment of orders received in 2023 by the end of 2024.

Together with previous agreements for 400 tons of seeds announced in February, this move positions Casterra to fulfill both current and future demands. The company leverages Evogene's 'GeneRator AI' technology to develop high-yielding, high-oil castor seeds, important for sustainable biofuel production.

Casterra aims to establish a reliable seed production infrastructure, mitigating production risks and reinforcing its market position in the biofuel industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
none
-
Rhea-AI Summary

Evogene (Nasdaq: EVGN) announces the release of its first quarter 2024 financial results on May 23, 2024. A conference call is scheduled for 9:00 AM ET to discuss the results. Register in advance to join the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none

FAQ

What is the current stock price of Evogene (EVGN)?

The current stock price of Evogene (EVGN) is $0.8778 as of February 27, 2026.

What is the market cap of Evogene (EVGN)?

The market cap of Evogene (EVGN) is approximately 7.5M.

EVGN Rankings

EVGN Stock Data

7.50M
8.63M
Biotechnology
Healthcare
Link
Israel
Rehovot

EVGN RSS Feed